DE60312997D1 - Nf-kb-inhibitoren - Google Patents
Nf-kb-inhibitorenInfo
- Publication number
- DE60312997D1 DE60312997D1 DE60312997T DE60312997T DE60312997D1 DE 60312997 D1 DE60312997 D1 DE 60312997D1 DE 60312997 T DE60312997 T DE 60312997T DE 60312997 T DE60312997 T DE 60312997T DE 60312997 D1 DE60312997 D1 DE 60312997D1
- Authority
- DE
- Germany
- Prior art keywords
- kappab
- inhibitors
- diseases
- activation
- aminothiophene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- GLQWRXYOTXRDNH-UHFFFAOYSA-N thiophen-2-amine Chemical compound NC1=CC=CS1 GLQWRXYOTXRDNH-UHFFFAOYSA-N 0.000 abstract 2
- 102000001284 I-kappa-B kinase Human genes 0.000 abstract 1
- 108060006678 I-kappa-B kinase Proteins 0.000 abstract 1
- 102000003945 NF-kappa B Human genes 0.000 abstract 1
- 108010057466 NF-kappa B Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 230000026731 phosphorylation Effects 0.000 abstract 1
- 238000006366 phosphorylation reaction Methods 0.000 abstract 1
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38655702P | 2002-06-06 | 2002-06-06 | |
| US386557P | 2002-06-06 | ||
| PCT/US2003/016876 WO2003104219A1 (en) | 2002-06-06 | 2003-05-29 | Nf-kb inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60312997D1 true DE60312997D1 (de) | 2007-05-16 |
| DE60312997T2 DE60312997T2 (de) | 2007-12-13 |
Family
ID=29736178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60312997T Expired - Fee Related DE60312997T2 (de) | 2002-06-06 | 2003-05-29 | Nf-kb-inhibitoren |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7300952B2 (de) |
| EP (1) | EP1532135B1 (de) |
| JP (1) | JP2005532359A (de) |
| AT (1) | ATE358673T1 (de) |
| AU (1) | AU2003240935A1 (de) |
| DE (1) | DE60312997T2 (de) |
| ES (1) | ES2285125T3 (de) |
| WO (1) | WO2003104219A1 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003270701B2 (en) | 2002-10-31 | 2009-11-12 | Amgen Inc. | Antiinflammation agents |
| WO2004110352A2 (en) | 2003-05-16 | 2004-12-23 | The Regents Of The University Of California | Compounds having activity in increasing ion transport by mutant-cftr and uses thereof |
| CN1950378A (zh) * | 2004-05-04 | 2007-04-18 | 霍夫曼-拉罗奇有限公司 | 作为ikk抑制剂的噻吩并哒嗪类化合物 |
| EP1745050A1 (de) * | 2004-05-04 | 2007-01-24 | F.Hoffmann-La Roche Ag | Thienopyridine als ikk-inhibitoren |
| US7812018B2 (en) | 2006-02-16 | 2010-10-12 | Millennium Pharmaceuticals, Inc. | Alpha carbolines and uses thereof |
| WO2008069102A1 (ja) * | 2006-12-06 | 2008-06-12 | Calpis Co., Ltd. | 炎症性腸疾患予防治療剤 |
| JP5312466B2 (ja) | 2008-10-02 | 2013-10-09 | 旭化成ファーマ株式会社 | ８位置換イソキノリン誘導体及びその用途 |
| US10954222B2 (en) * | 2012-02-09 | 2021-03-23 | National University Corporation Tokyo Medical And Dental University | Benzothiophene compound, alternative autophagy-inducing agent and anticancer agent including the compound as active ingredient, and method for screening for compound having anticancer activity |
| EP3194366A1 (de) * | 2014-09-15 | 2017-07-26 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Benzothiophen-, benzyloxybenzyliden- und indolinderivate zur behandlung von tuberkulose |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4782080A (en) | 1985-09-16 | 1988-11-01 | Merck & Co., Inc. | N-alkenyl-2-hydroxybenzo(b)thiophene-3-carboxamide derivatives as dual cyclooxygenase and lipoxygenase inhibitors |
| US6545027B1 (en) | 1995-06-07 | 2003-04-08 | Eli Lilly And Company | Methods of modulating NF-kB transcription factor |
| JP2001523253A (ja) | 1997-04-30 | 2001-11-20 | イーライ・リリー・アンド・カンパニー | ベンゾ［ｂ］チオフェン類の製造のための中間体および方法 |
| JP2004523476A (ja) * | 2000-10-12 | 2004-08-05 | スミスクライン・ビーチャム・コーポレイション | ＮＦ−κＢ阻害剤 |
-
2003
- 2003-05-29 US US10/517,111 patent/US7300952B2/en not_active Expired - Fee Related
- 2003-05-29 AU AU2003240935A patent/AU2003240935A1/en not_active Abandoned
- 2003-05-29 DE DE60312997T patent/DE60312997T2/de not_active Expired - Fee Related
- 2003-05-29 ES ES03731435T patent/ES2285125T3/es not_active Expired - Lifetime
- 2003-05-29 EP EP03731435A patent/EP1532135B1/de not_active Expired - Lifetime
- 2003-05-29 WO PCT/US2003/016876 patent/WO2003104219A1/en not_active Ceased
- 2003-05-29 JP JP2004511289A patent/JP2005532359A/ja not_active Withdrawn
- 2003-05-29 AT AT03731435T patent/ATE358673T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005532359A (ja) | 2005-10-27 |
| WO2003104219A1 (en) | 2003-12-18 |
| EP1532135A1 (de) | 2005-05-25 |
| ES2285125T3 (es) | 2007-11-16 |
| US20060058371A1 (en) | 2006-03-16 |
| ATE358673T1 (de) | 2007-04-15 |
| DE60312997T2 (de) | 2007-12-13 |
| EP1532135B1 (de) | 2007-04-04 |
| US7300952B2 (en) | 2007-11-27 |
| EP1532135A4 (de) | 2005-11-09 |
| AU2003240935A1 (en) | 2003-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60229975D1 (de) | Nf-kb-inhibitoren | |
| PL1660507T5 (pl) | Inhibitory proteazomu oraz sposoby ich stosowania | |
| ATE396731T1 (de) | Thiazole zur verwendung als inhibitoren von protein-kinasen | |
| ATE513550T1 (de) | Verwendung eines ibat-hemmers zur behandlung oder vorbeugung von verstopfung | |
| SE0203752D0 (sv) | New compounds | |
| DE60332433D1 (de) | Azolylaminoazine als proteinkinasehemmer | |
| ATE418336T1 (de) | Verwendung von i kappa b-kinase inhibitoren in der schmerztherapie | |
| ATE423087T1 (de) | Proteasome inhibitoren und deren verwendung | |
| IS7812A (is) | Afleiður 4-tetrazólýl-4-fenýlpiperidíns til þess að meðhöndla verk | |
| IL229124A0 (en) | Inhibitors with a mutant form of kit | |
| DE60312997D1 (de) | Nf-kb-inhibitoren | |
| ATE382048T1 (de) | Pyrazolopyrimdine als hemmstoffe cyclin abhängiger kinasen | |
| DE60322898D1 (de) | Verwendung von isoflavonen zur förderung des schlankheitseffekts | |
| MY162518A (en) | Proteasome inhibitors and methods of using the same | |
| ATE443044T1 (de) | Tace inhibitoren | |
| WO2003086309A3 (en) | NF-κB INHIBITORS | |
| ATE534380T1 (de) | Glepp-1-hemmer bei der behandlung von autoimmun- und/oder entzündungskrankheiten | |
| ATE536874T1 (de) | Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen | |
| ATE376416T1 (de) | Verwendung von ambroxol zur behandlung von chronischen schmerzen | |
| DE60220825D1 (de) | Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks | |
| ATE486598T1 (de) | Kinase inhibitoren und deren verwendung | |
| ATE548040T1 (de) | Verwendung von vasopeptidase-inhibitoren zur behandlung von nephropathie | |
| ATE488238T1 (de) | Verwendung von thiazolbenzo-heterocyclenfür die behandlung von multipler sklerose | |
| DE50200635D1 (de) | Verwendung von inhibitoren von ikk-beta und verfahren zum auffinden solcher inhibitoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |